Journal: Frontiers in Pharmacology

Article Title: Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17–mediated inflammation

doi: 10.3389/fphar.2026.1754729

Figure Lengend Snippet: Integrated workflow for target prediction and experimental validation of Lico B in psoriasis. Bioinformatic analyses, including WGCNA module construction, gene–trait correlation analysis, multi-database target intersection (GEO, GeneCards, TTD), molecular docking, and SPR analysis were used to identify candidate targets of Lico B. Subsequent in vitro and in vivo experiments—comprising Western blotting, qPCR, immunofluorescence staining, and flow cytometry in IL-17–stimulated keratinocytes and IMQ-induced psoriatic mice—were conducted to validate the therapeutic mechanisms of Lico B.

Article Snippet: The IL-17 group was treated with 100 ng/mL IL-17 (Proteintech; HZ-1113); the Lico B group received 9 μM Lico B (MCE; HY-N3388); the IL-17 + Lico B group was co-treated with IL-17 and Lico B; and the control group was treated with PBS.

Techniques: Biomarker Discovery, In Vitro, In Vivo, Western Blot, Immunofluorescence, Staining, Flow Cytometry

Journal: Frontiers in Pharmacology

Article Title: Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17–mediated inflammation

doi: 10.3389/fphar.2026.1754729

Figure Lengend Snippet: Schematic illustration of lico B treatment in psoriasis. Lico B modulates lipid metabolic pathways by suppressing SCD1-dependent metabolic reprogramming and reducing lipid droplet accumulation in keratinocyte, while simultaneously attenuating the TH17/IL-17 axis. Through concurrent regulation of keratinocyte metabolism and inflammatory cytokine production, Lico B ameliorate psoriatic skin pathology.

Article Snippet: The IL-17 group was treated with 100 ng/mL IL-17 (Proteintech; HZ-1113); the Lico B group received 9 μM Lico B (MCE; HY-N3388); the IL-17 + Lico B group was co-treated with IL-17 and Lico B; and the control group was treated with PBS.

Techniques:

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Cytokine primers/probes for RT-qPCR identification

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques:

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Th17-associated genes upregulated >9-fold in response to M. bovis PPD after M. bovis infection

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques:

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: IL-17A responses (protein) to M. bovis infection of cattle. Treatment groups included noninfected (n = 7), strain 95-1315-infected (white-tailed deer M. bovis isolate; n = 8), and strain 10-7428-infected (Holstein M. bovis isolate; n = 8) calves, with the experimental design described in Table 1. Whole blood was collected into heparinized tubes and stimulated with 1 μg/ml rESAT-6:CFP10 (A), 20 μg/ml M. avium PPD (Lelystad; Prionics Ag) (B), 20 μg/ml M. bovis PPD (Lelystad; Prionics Ag) (C), or medium alone (no stimulation) for 16 h at 39°C. Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech). Data (mean ± SEM) are presented as the change in nanograms per milliliter (i.e., antigen stimulation minus medium alone) for each treatment group at the indicated time points relative to challenge. a to c, different letters indicate that responses differ for the given time point (P < 0.05, ANOVA followed by Tukey's multiple-comparison test).

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Infection, Enzyme-linked Immunosorbent Assay

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Diagnostic capacity 8 weeks after M. bovis challenge ( M. bovis PPD minus M. avium PPD)

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Diagnostic Assay, Infection

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: IFN-γ and IL-17A responses to vaccination and subsequent challenge with virulent M. bovis. Treatment groups included nonvaccinated animals (n = 10), BCG-vaccinated animals (n = 9), and animals vaccinated with BCG mutants (i.e., BCG Δfdr8, BCG ΔleuCD Δpks16, BCG ΔmetA, and BCG ΔmmaA4) (n = 10). The virulent M. bovis strain 10-7428 was administered by aerosol to all calves 3.5 months after vaccination, and calves were euthanized 4.5 months after challenge (Table 1). Whole blood was collected into heparinized tubes and stimulated with 20 μg/ml M. bovis PPD (Lelystad; Prionics Ag) (A), 1 μg/ml rAg85A-rTB10.4 (B), 1 μg/ml rESAT-6:CFP10 (C), or medium alone (no stimulation) for 16 h at 39°C. Plasma was harvested for IFN-γ (left) and IL-17A (right) analyses using commercial ELISA kits (Bovigam [Prionics Ag] and bovine IL-17A ELISA VetSet [Kingfisher Biotech]). Data (mean ± SEM) are presented as the change in nanograms per milliliter (i.e., antigen stimulation minus medium alone) for each treatment group at the indicated time points relative to vaccination (Vacc) or challenge. a to c, different letters indicate that responses differ for the given time point (P < 0.05, ANOVA followed by Tukey's multiple-comparison test).

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Correlation of IL-17A and IFN-γ responses. Treatment groups included nonvaccinated animals (n = 10), BCG-vaccinated animals (n = 9), and animals vaccinated with BCG mutants (i.e., BCG Δfdr8, BCG ΔleuCD Δpks16, BCG ΔmetA, and BCG ΔmmaA4) (n = 10). Virulent M. bovis strain 10-7428 was administered by aerosol to all calves 3.5 months after vaccination, and calves were euthanized 4.5 months after challenge (Table 1). Whole blood was collected into heparinized tubes from all calves 11 weeks after vaccination, 2.5 weeks after M. bovis challenge, and 10 weeks after M. bovis challenge and were stimulated with 20 μg/ml M. bovis PPD (Lelystad; Prionics Ag) (A), 1 μg/ml rAg85A-rTB10.4 (B), 1 μg/ml rESAT-6:CFP10 (C), or medium alone (no stimulation) for 16 h at 39°C, and plasma was harvested for IFN-γ and IL-17A analyses using ELISA kits (Bovigam [Prionics Ag] and bovine IL-17A ELISA VetSet [Kingfisher Biotech]). Data represent the changes in nanograms per milliliter (log10) (i.e., antigen stimulation minus medium alone) for IFN-γ versus IL-17A responses for each individual animal at each time point (n = 87). Prior to analysis and graphing, data were transformed for positive skewness with zero values using the following formula: new x = log10(x + 1).

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunosorbent Assay, Transformation Assay

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Dampening of IL-17A responses (ELISPOT assay) to M. bovis infection with prior BCG vaccination. Treatment groups included nonvaccinated animals (n = 10) and vaccinated animals (n = 19). The vaccinated group consisted of animals vaccinated with BCG (n = 9) or BCG mutants (i.e., BCG Δfdr8, BCG ΔleuCD Δpks16, BCG ΔmetA, and BCG ΔmmaA4; n = 10). Virulent M. bovis strain 10-7428 was administered by aerosol to all calves 3.5 months after vaccination, and calves were euthanized 4.5 months after M. bovis challenge (Table 1). For IL-17A ELISPOT analysis, PBMCs (2 × 105 PBMCs/well) were stimulated with 10 μg/ml M. bovis PPD (A), 3 μg/ml rAg85A-rTB10.4 (B), or 3 μg/ml rESAT-6:CFP10 (C) for 18 h prior to spot development and counting, as described in Materials and Methods. Results (mean ± SEM) are expressed as spot-forming units (sfu) per 2 × 105 cells for each treatment group at the indicated time points relative to vaccination (Vacc) or challenge. *, response differs from that for nonvaccinated animals at that time point (P < 0.05, as determined by ANOVA followed by Tukey's multiple-comparison test).

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunospot, Infection

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Association of ESAT-6:CFP10-specific IFN-γ and IL-17A responses with mycobacterial burdens in the 2014 vaccine efficacy study. Treatment groups included nonvaccinated animals, BCG-vaccinated animals, and animals vaccinated with BCG mutants (i.e., BCG Δfdr8, BCG ΔleuCD Δpks16, BCG ΔmetA, and BCG ΔmmaA4). Virulent M. bovis strain 10-7428 was administered by aerosol to all calves 3.5 months after vaccination, and calves were euthanized 4.5 months after M. bovis challenge (Table 1). Whole blood from all calves was collected into heparinized tubes at 2.5 and 10 weeks after challenge and stimulated with 1 μg/ml rESAT-6:CFP10 or medium alone (no stimulation) for 16 h at 39°C, and plasma was harvested for IFN-γ and IL-17A analyses using commercial ELISA kits (Bovigam [Prionics Ag] and bovine IL-17A ELISA VetSet [Kingfisher Biotech]). Mycobacterial burdens were determined by serial dilution culture of entire tracheobronchial lymph node homogenates and are presented as culture-forming units per gram of tissue. Groups were split based on mycobacterial burdens of 0 CFU/g (n = 14) or >0 CFU/g (n = 15). All 14 animals in the 0-CFU/g group were vaccinated animals. In the >0-CFU/g group, 5/15 animals were vaccinated animals and 10/15 were nonvaccinated animals. Data (mean ± SEM) are presented as IFN-γ (left) and IL-17A (right) responses (changes in nanograms per milliliter, i.e., antigen stimulation minus medium alone) to rESAT-6:CFP10 at 3 weeks after M. bovis challenge (A) and 10 weeks after M. bovis challenge (B), as related to mycobacterial burdens determined at necropsy 4.5 months after challenge. Similar results were obtained for responses to M. bovis PPD (data not shown). Student's t test P values are provided in the upper left corner of each graph.

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunosorbent Assay, Serial Dilution

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Association of ESAT-6:CFP10-specific IFN-γ and IL-17A responses with lesion severity (i.e., gross pathology scores) in the 2014 vaccine efficacy study. Treatment groups included nonvaccinated animals, BCG-vaccinated animals, and animals vaccinated with BCG mutants (i.e., BCG Δfdr8, BCG ΔleuCD Δpks16, BCG ΔmetA, and BCG ΔmmaA4). Virulent M. bovis strain 10-7428 was administered by aerosol to all calves 3.5 months after vaccination, and calves were euthanized 4.5 months after M. bovis challenge (Table 1). Whole blood from all calves was collected into heparinized tubes at 2.5 and 10 weeks after challenge and stimulated with 1 μg/ml rESAT-6:CFP10 or medium alone (no stimulation) for 16 h at 39°C, and plasma was harvested for IFN-γ and IL-17A analyses using ELISA kits (Bovigam [Prionics Ag] and bovine IL-17A ELISA VetSet [Kingfisher Biotech]). The lesion severity for lungs and lymph nodes (i.e., mediastinal and tracheobronchial lymph nodes) was determined using a semiquantitative scoring system adapted from that described by Vordermeier et al. (24). Groups were split based on gross pathology scores of 0 (n = 12; all vaccinated animals), 1 to 5 (n = 7; all vaccinated animals), or 6 to 22 (n = 10; all nonvaccinated animals). Data (mean ± SEM) are presented as IFN-γ (left) and IL-17A (right) responses (changes in nanograms per milliliter, i.e., antigen stimulation minus medium alone) to rESAT-6:CFP10 at 3 weeks after M. bovis challenge (A) and 10 weeks after M. bovis challenge (B), as related to gross pathology scores determined at necropsy 4.5 months after challenge. Similar results were obtained for responses to M. bovis PPD (data not shown). *, response differs from the other responses in the graph (P < 0.05, ANOVA followed by Tukey's multiple-comparison test).

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Interleukin-17A as a Biomarker for Bovine Tuberculosis

doi: 10.1128/CVI.00637-15

Figure Lengend Snippet: Correlation of ESAT-6:CFP10-specific IL-17A responses at 8 weeks after M. bovis challenge with lesion severity and mycobacterial burden in the 2007 vaccine efficacy study. Treatment groups included nonvaccinated, BCG-vaccinated, and M. bovis ΔRD1-vaccinated animals. Virulent M. bovis strain 95-1315 was administered by aerosol to all calves 3 months after vaccination, and calves were euthanized 4.5 months after M. bovis challenge (Table 1). Eight weeks after M. bovis challenge, PBMCs (2 × 105 PBMCs/well) were stimulated with 1 μg/ml rESAT-6:CFP10 or medium alone at 39°C for 16 h, and supernatants were harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech). For evaluation of gross pathology, lungs and lymph nodes (mediastinal and tracheobronchial) were evaluated using a semiquantitative scoring system (24). Mycobacterial burdens were determined by culture of a series of dilutions of entire tracheobronchial lymph node homogenates and are presented as CFU per gram of tissue (26). Data (mean ± SEM) are presented as changes in nanograms per milliliter (i.e., antigen stimulation minus medium alone) for each treatment group based on gross pathology scores (A and C) or mycobacterial burdens (B and D). Student's t test P values are provided in the upper left corner of each graph.

Article Snippet: Plasma was harvested for IL-17A analysis by ELISA (bovine IL-17A ELISA VetSet; Kingfisher Biotech).

Techniques: Enzyme-linked Immunosorbent Assay